Angiotech Launches Orthopedics Strategy With Orthovita Pact, NeuColl Buy
This article was originally published in The Gray Sheet
Executive Summary
Angiotech's marketing agreement with Orthovita for its CoStasis hemostatic spray, and NeuColl purchase, provide an initial orthopedics presence as the firm develops drug/device combinations for the sector
You may also be interested in...
Orthovita launches Vitagel
Firm's 40-person direct sales team targets more than 500 hospitals in the U.S. following launch of the hemostatic spray, indicated to control bleeding in cardiovascular, spinal, orthopedic and general surgery procedures. Orthovita's marketing partner Angiotech expects to transfer Vitagel production capabilities to the former firm's Malvern, Penn. facility by Q3 2005. The device, originally known as CoStasis and marketed by Tyco/U.S. Surgical, received PMA approval in 2000 (1"The Gray Sheet" June 28, 2004, p. 30)...
Orthovita launches Vitagel
Firm's 40-person direct sales team targets more than 500 hospitals in the U.S. following launch of the hemostatic spray, indicated to control bleeding in cardiovascular, spinal, orthopedic and general surgery procedures. Orthovita's marketing partner Angiotech expects to transfer Vitagel production capabilities to the former firm's Malvern, Penn. facility by Q3 2005. The device, originally known as CoStasis and marketed by Tyco/U.S. Surgical, received PMA approval in 2000 (1"The Gray Sheet" June 28, 2004, p. 30)...
Angiotech in search of AAA stent-graft
University of British Columbia will license to pharmaceutical firm its next-generation stent-endograft coating technology to treat abdominal aortic aneurysms, Angiotech notes March 17. Jointly developed, the drug coating promotes fibrous (scar) tissue growth and creates a biologic anchor for the stent. Angiotech has begun seeking device development partners...